Ionising radiation is a well-established human carcinogen and is known to cause tumours in various organs. On the other hand, radiation is a main therapeutic modality in the treatment of a variety of human cancers. In the past two decades, there has been plenty of evidence that radiation can induce bystander/non-target effects *in vitro* and *in vivo*. However, the precise mechanisms are still unclear ([@bib13], [@bib14]; [@bib8]). In *in vitro* studies, there is evidence that reactive oxygen/nitrogen species and cytokines are involved in mediating the non-targeted response in subconfluent cultures or from medium transfer studies. On the other hand, gap junction-mediated cell-cell communications have been shown to be critical for bystander effects in confluent cultures of either human or rodent origin. It is likely that a combination of pathways is involved in producing a bystander response. Using primary human fibroblasts, we showed recently that the cyclo-oxygenase-2 (COX-2) signalling cascade, including the activation of mitogen activated protein kinase pathways, has an essential role in the bystander process ([@bib21]). Furthermore, we found that mitochondria had an important role in radiation-induced bystander effect, partially via mitochondria-dependent regulation of iNOS and COX2 signalling pathways, which are under NF-*κ*B regulation ([@bib22]). More recently, there is evidence that bone marrow cells of both CBA/Ca and C57BL/6 mice are responsive to signals produced by either irradiated CBA/Ca or C57BL/6 mice, and the responses are mediated by the cytokines converging on a COX-2 dependent pathway ([@bib16]).

Using *gpt* delta transgenic mice, we reported recently that radiation can induce DNA damage and mutagenesis in the out of field lung and liver tissues after a 5 Gy dose of X-rays delivered to the lower abdomen of otherwise shielded animals. Furthermore, the induction of COX-2 coincided with an increase in prostaglandin and *spi*^-^ mutations in out of field lung tissues ([@bib2]). As a follow-up study, here, we examined the possible pathways involved in partial body irradiation induced non-targeted responses in *gpt* delta transgenic mice.

MATERIALS AND METHODS
=====================

Animal and drug treatment schedule
----------------------------------

Nimesulide (Sigma Aldrich, St Louis, MO, USA), a selected COX-2 inhibitor ([@bib4]), was dissolved in PBS containing 0.2% DMSO, freshly prepared on the day of the experiments. Four groups of adult male *gpt* delta transgenic mice were used in this study. There were two non-irradiated groups, consisting of three animals each, treated with vehicle (PBS with 0.2% DMSO, used for dilution of Nimesulide, 0.3 ml per animal, intraperitoneal injection) or Nimesulide (0.3 ml per animal, 1.5 mg kg^−1^, intraperitoneal injection) only. The other two parallel groups were partial body irradiated with 5 Gy of X-rays as described previously ([@bib2]) after pretreatment by vehicle or Nimesulide. Each partial body irradiation group consisted of five mice. To be consistent with our previous study, a 5 Gy dose was chosen in the current work. On the other hand, treatments with gamma-knife for CNS tumours and with hadrontherapy for other solid tumours involved doses in excess of 10--15 Gy in a single fraction been used with the intent to cure ([@bib12]; [@bib7]). As such, with modern advances in radiotherapy regimen, doses larger than 2 Gy fractions are no longer clinically irrelevant. All of the drugs were administered for five consecutive days. The last treatment of drugs was given 2 h before irradiation. Animals in the four groups were sacrificed at 24 h after irradiation. Lung and liver tissues were collected and processed for further molecular studies. A portion of each tissue was frozen in liquid nitrogen while the rest of each tissue was fixed in 10% formalin.

Western blot analysis
---------------------

Cell lysates (50--100 *μ*g protein) were resolved on 4--12% gradient SDS--PAGE gel (Invitrogen, Carlsbad, CA, USA), and processed according to standard protocols. Various antibodies were used, including anti-COX-2 (Cayman, Ann Arbor, MI, USA), anti-TGF-*β*1(Cell Signaling, Danvers, MA, USA), anti-TGF-*β* receptor type-1 (TGFBR1) (Abcam, Cambridge, MA, USA), anti-TGF-*β* receptor type-2 (TGFBR2) (Santa Cruz Biotech, Santa Cruz, CA, USA), anti-TNF-*α*(Cell Signaling), anti-TNF receptor 1(TNF-R1) (Santa Cruz Biotech), anti-extracellular signal-regulated kinase (ERK) (Cell Signaling), anti-phospho-ERK(Thr^202^/Tyr^204^), (Cell Signaling), anti-c-Jun N-terminal kinase (JNK) (Cell Signaling), anti-phospho-JNK(Thr^183^/Tyr^185^) (Cell Signaling), anti- nuclear factor kappa-B (NF*κ*B) p65 (Cell Signaling), anti-phospho-NF*κ*B p65(Ser^536^) (Cell Signaling), anti-AKT (Cell Signaling), anti-phospho-AKT(Ser^473^) (Cell Signaling), anti-Smad2 (Cell Signaling), anti-phosho-Smad2(Ser^465/467^) (Cell Signaling), anti-Rac1/2/3 (Cell Signaling), anti-phosho-Rac1/cdc42(Ser^71^) (Cell Signaling) and monoclonal anti-*β*-actin (Sigma Aldrich) (optimal dilutions of antibodies were 1:100--1:1000). The secondary antibodies (anti-rabbit or anti-mouse, GE Healthcare, Piscataway, NJ, USA) were conjugated with horseradish peroxidase (HRP) (dilution 1:5000). Chemiluminescent signal was detected using the ECL system (GE Healthcare) and quantified using Image J software (NIH, Bethesda, MD, USA) and normalised to the *β*-actin expression level.

Immunohistochemistry staining
-----------------------------

Immunohistochemistry staining was performed using various primary antibodies and specific secondary antibodies including anti-COX-2 (Cayman), anti-8-OHdG (Abcam), anti-TGF-*β*1 (Sigma Aldrich), anti- TGFBRI (Abcam) and anti-phosho-ERK (Cell Signaling) as previously described ([@bib1]). The slides were analysed by using an Olympus CX31 microscope connected with a Motic MC Camera (2.0 megapixel; MC2001interface, Sterling Heights, MI, USA). Paint Shop Pro (Sterling Heights, MI, USA) was used to quantify the protein expression level on each slide ([@bib1]). The data were expressed as the mean±s.e. of the mean (s.e.m.) of the relative grade of luminescence obtained from each slide.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

Microwell plates (Nunc Maxisorp, eBioscience, San Diego, CA, USA) were coated with 100 *μ*l of capture antibody in coating buffer (Invitrogen) overnight at 4 °C. For blocking, 200 *μ*l of 3% bovine serum albumin (BSA) in PBS was added to wells and incubated for 1 h at 20 °C. Plasma was diluted 1:5 in 2% BSA in PBS containing 0.05% Tween 20 (PBST) to the wells followed immediately by addition of biotin-conjugated detection antibody, diluted in 50 *μ*l of 2% BSA-PBST. After 90 min incubation at 20 °C with shaking, plates were washed (4 × PBST) and streptavidin-HRP was added, diluted in 100 *μ*l of 2% BSA-PBST. Following 1 h incubation at 20 °C, microwells were washed four times and 100 *μ*l of tetramethylbenzidine (TMB, Thermo Scientific, Rockford, IL, USA) added for 15--30 min at 20 °C. Reactions were stopped by addition of 0.9 ℳ H~2~SO~4~ (50 *μ*l) and product absorbance was determined at 450 nm ([@bib15]).

Statistical analysis
--------------------

All data were expressed as mean±s.e. of mean. Differences between groups were tested for statistical significance using a Student\'s *t*-test. A *P*-value less than 0.05 denoted the presence of a statistically significant difference between groups.

Results
=======

Role of COX-2 inhibitor in lower abdominal irradiation-induced DNA damage in out of field lung tissues
------------------------------------------------------------------------------------------------------

Consecutive pretreatment with Nimesulide (1.5 mg kg^−1^ body weight, intraperitoneal injection) for 5 days did not affect COX-2 expression in lung tissues of non-irradiated animals ([Figure 1A](#fig1){ref-type="fig"}). In our previous study, we found that both female and male animals showed a similar induction peak of COX-2 at 24 h after irradiation ([@bib2]). In contrast, pretreatment of Nimesulide reduced COX-2 expression in non-targeted lung tissues by 30% relative to vehicle control animals at 24 h after lower abdominal irradiation ([Figure 1A](#fig1){ref-type="fig"}). Similar to western blot, results from immunohistochemistry staining showed a 30% suppression efficiency of COX-2 in non-targeted lung bronchial epithelial cells by Nimesulide, relative to the vehicle pretreated group at 24 h after partial body irradiation (*P*\<0.05, [Figure 1B](#fig1){ref-type="fig"}). Compared with the vehicle control group, Nimesulide reduced induction of PGE~2~, a major isoform of prostaglandin by 30% in bystander lung tissues (3.9-fold *vs* 2.6-fold, respectively, [Figure 1C](#fig1){ref-type="fig"}). The efficiency of PGE~2~ suppression by Nimesulide was consistent with that of COX-2 among the same non-targeted lung tissues after lower abdominal irradiation. As a consequence of inhibiting the production of prostaglandin, Nimesulide efficiently reduced radiation-induced oxidative DNA damage in non-targeted lung tissues by 40% compared with vehicle group after lower abdominal irradiation (*P*\<0.05, [Figure 1D](#fig1){ref-type="fig"}).

Alteration of Cytokines and their receptors in plasma and bystander tissues after partial body irradiation
----------------------------------------------------------------------------------------------------------

The plasma levels of released cytokines, especially TGF-*β* and TNF-*α,* after PBIR were examined using ELISA. A fluctuation of both cytokines in plasma at a series of time points after PBIR was observed although the difference was not statistically significant comparing with the levels in controls ([Figures 2A and B](#fig2){ref-type="fig"}). Further, we examined the expression level of ligands and related receptors of TGF-*β* and TNF-*α* in lung tissues using western blots after PBIR. As shown in [Figure 3A](#fig3){ref-type="fig"}, TGF-*β* expression was significantly elevated in bystander lung tissues at 24 h after partial body irradiation, but decreased at 48 h. Following the upregulation of TGF-*β*, TGF-*β* receptors, especially TGFBR1, were gradually elevated in bystander lung tissues at 48 h after irradiation and decreased to basal level at 72 h ([Figure 3B](#fig3){ref-type="fig"}). Quantification analysis of western blot bands showed that TGF-*β* ligands responded earlier than TGFBR1 and TGFBR2, respectively ([Figure 3B](#fig3){ref-type="fig"}). In contrast, expression of TNF-*α* ligands and receptors in bystander lung tissues was not significantly different from that in the non-treated lung tissues at a series of time points after partial body irradiation ([Figure 3C](#fig3){ref-type="fig"}). Consistent with our previous finding that COX-2 induction was tissue-specific but not gender-specific ([@bib2]), there was a difference in the expression of TGF-*β* receptor levels between non-targeted livers and lungs of the same animals. There was a negligible level of TGFBR1 in liver tissue but a high level in lung tissues, which might result in different sensitivity of TGF-*β* signals in lung *vs* liver ([Figure 3D](#fig3){ref-type="fig"}). The difference in TGF-*β* receptors was consistent with different induction of COX-2 and DNA damage response in bystander lung and liver tissues after treatment, as shown previously ([@bib2]).

Using immunohistochemistry staining, we determined the location of TGF-*β* ligands and receptors in non-targeted lung tissues after PBIR. As all end points obtained with a 6c Gy dose of WBIR (control for scattering dose) were similar to non-irradiated controls, the result obtained with the 6c Gy dose was shown. TGF-*β*1 was predominantly expressed in stromal and alveoli cells but not in bronchial epithelial cells of both scattered dose control and PBIR 5 Gy groups ([Figures 4A and B](#fig4){ref-type="fig"}). In contrast to the induction of COX-2 shown earlier, there was no significant difference in the distribution of TGF-*β* in lung tissues after PBIR *vs* the scattering dose WBIR group. Quantification analysis did not show a significant difference in the expression of TGF-*β* in bronchial epithelial cells between non-irradiated control and partially irradiated animals (PBIR 5 Gy, data not shown). In contrast to the results obtained with TGF-*β*, TGFBR1 was found to distribute mainly in bronchial epithelial cells but not in neighbouring stromal cells ([Figures 4C and D](#fig4){ref-type="fig"}). TGFBR1 was significantly increased in non-targeted lung bronchial epithelial cells compared with controls, which was consistent with the expression pattern and location of COX-2 induced by partial body irradiation.

Activation of multiple TGF-*β* induced pathways in non-targeted lung tissues
----------------------------------------------------------------------------

There are two major TGF-*β* related signalling pathways, Smad-dependent and Smad-independent pathways. Activation of TGF-*β* signalling leads to the induction of multiple signalling pathways involving Smad2, Rac1, ERK, JNK, NF*κ*B and AKT as described ([@bib19]). The expression of Smad2, an important factor in the Smad-dependent TGF-*β* pathway in bystander lung tissues was examined after PBIR at different time points. p-Smad2 levels were elevated at 24 h after treatment and maintained through 48 h before returning to basal levels at 72 h after irradiation, consistent with the induction of TGF-*β* and COX-2 in the non-targeted lung tissues ([Figure 5A](#fig5){ref-type="fig"}).

Besides the Smad-dependent pathway, we examined the Smad-independent signalling pathways involving Rac1, ERK, JNK, AKT and NF*κ*B ([@bib10]). Rac1 did not show any changes in non-targeted lung tissues at a series of time points after irradiation ([Figure 5A](#fig5){ref-type="fig"}). In contrast, NF*κ*B, AKT, ERK and JNK, were activated by phosphorylation, which are critical upstream events controlling COX-2 expression. The activated forms of NF*κ*B, AKT, ERK and JNK were all dramatically upregulated in bystander lung tissues at different time points after PBIR ([Figures 5B and E](#fig5){ref-type="fig"}). Phosphorylation of p65 signified an upregulation of NF*κ*B activity at 3 h after treatment and that was maintained above basal levels within 24 h after irradiation, indicating a persistent response in non-targeted lung tissues to the signals derived from the irradiated area ([Figure 5B](#fig5){ref-type="fig"}). Similar to NF*κ*B, AKT showed activation in bystander lung tissues at a series of time points after treatment ([Figure 5C](#fig5){ref-type="fig"}). Similarly, expression of ERK and JNK showed a bi-phasic pattern in the bystander lung tissues with an initial peak induction at 1 hr after irradiation and a later, more sustained secondary peak at 24--48 h before returning to basal levels at 72 h ([Figures 5D and E](#fig5){ref-type="fig"}). Immunohistochemistry staining showed that p-ERK was predominantly localised in non-targeted bronchial epithelial cells, consistent with induction of COX-2 and TGFBR1 at 24 h after lower abdomen irradiation (Data not shown).

DISCUSSION
==========

We have shown previously that the induction of COX-2 in bystander lung tissue is tissue-specific, but not gender dependent ([@bib2]). Tissue-specific bystander effects have also been shown in other *in vivo* systems. Previous studies have shown that partial body irradiation induced different epigenetic responses in bystander organs such as skin and spleen ([@bib9]), whereas no differential response was seen in the same organism by acute *vs* fractionated exposure. There is evidence that whole-body irradiation of animals by either X-rays or *γ*-rays significantly induces an increase in TNF-*α* and a decrease in TGF-*β* levels in plasma ([@bib15]). Our present studies show that liver, in contrast to the lung, showed no induction of TGFBR1 and lacks the subsequent downstream signalling responses, including JNK and NF*κ*B, that are necessary for the induction of COX-2 as shown previously ([@bib21]). The lack of receptor provides a reasonable explanation for the differential induction of COX-2 levels between the lung and the liver in partially irradiated animals.

There are two possible pathways whereby signals from irradiated lower abdomen can be transmitted to non-targeted lung tissues. The first involves release of cytokine(s) from irradiated tissues/organs in the lower abdomen, circulation to non-targeted lung tissues and binding to their receptors on the corresponding cells to induce bystander effects such as upregulation of COX-2 and DNA damage in non-targeted lung tissues. Therefore, the change of cytokines in plasma could be associated with the upregulation of COX-2 in non-targeted lung tissues. However, our preliminary ELISA analysis did not show any significant change in the plasma level of either TGF*β* or TNF*α* as a function of time postpartial body irradiation whereas COX-2 was shown to be significantly induced in non-targeted lung tissues. A second possible mechanism of transferring damage signals is through circulation of lymphatic cells from exposed regions in the lower abdomen of animals to non-targeted lung tissues to activate downstream effects such as induction of COX-2 and DNA damage response. COX-2 is over-expressed with chronic inflammation and infiltration of macrophages, neutrophils and lymphocytes ([@bib3]). Previous studies have shown that cytokines, especially TGF-*β,* are induced in lung tissues during acute inflammation ([@bib20]). Interestingly, from the present studies, over-expression of TGF-*β* receptors did not colocalise with TGF-*β* in the same regions of bystander lung tissues. TGF-*β* was highly expressed in lung bronchial stromal cells and alveoli cells but TGF-*β* receptors were predominantly localised in bronchial epithelial cells where they colocalised with the induction of COX-2 and oxidative DNA damage after lower abdominal irradiation. There is evidence that TGF-*β* is involved in ROS induction and Ca^2+^ influx in bystander cells ([@bib18]; [@bib17]) and inhibition of TGF-*β* or ROS can reduce the bystander responses in cells. While the rationale for the differential expression of TGF-*β* and its receptors in specific bystander cell types is not known, it is clear that the TGF-*β* signalling pathway is involved in bystander responses in non-targeted lung tissues.

As demonstrated in the present studies, multiple TGF-*β* related signalling pathways, both Smad-dependent and Smad-independent, including Smad2, ERK, JNK, NF*κ*B (p65) and AKT, are activated in non-targeted lung tissues after lower abdominal irradiation. However, the expression kinetics appears to be different for each pathway. The expression of the Smad-2 pathway showed that there was only one peak within 3 days after irradiation, consistent with the change of TGF-*β* ligands and receptors in non-targeted lung tissues. In contrast, all the Smad-independent pathways examined, showed a biphasic expression profile, reminiscent of that reported for NF*κ*B regulated gene expression in human bystander lung cells *in vitro* ([@bib6]; [@bib5]). In the bystander lung tissues, the change in Smad-independent pathways is more complicated than in Smad-dependent pathways possibly because the former could be simultaneously regulated by other factors, but Smad-dependent pathways were primarily controlled by TGF-*β*.

On the basis of the *in vivo* results of this study, a working model of the signalling pathway for the radiation-induced bystander effect in non-targeted lung tissues after lower abdominal irradiation is proposed ([Figure 6](#fig6){ref-type="fig"}). After irradiation of the lower abdomen, irradiated lymphatic cells circulate and infiltrate into non-targeted lung tissues to induce expression of TGF-*β* ligands and receptors in different regions of the non-targeted lung tissues. The TGF-*β* ligands in stromal and alveoli cells bind to TGFBR1 in the bronchial epithelial cells to activate multiple downstream signalling pathways such as ERK, JNK, NF*κ*B, AKT and Smad2. Consequently, COX-2 is induced in non-targeted lung tissues, especially bronchial epithelial cells. COX-2 catalyses arachidonic acid to produce prostaglandin and further induces oxidative DNA damage in bronchial epithelial cells. Our current study highlights the importance of COX-2 as a mediator of *in vivo* non-targeted responses. Earlier studies by ([@bib11]) showed the induction of tumorigenesis in the brain after irradiation of the lower halves of neonatal *Ptch1*^+/−^ mice. Furthermore, their studies also indicated that pretreatment with a single dose of Nimesulid (1.5 mg kg^−1^) induced a non-significant reduction in apoptosis and double strand breaks in non-targeted brain tissues. However, the study was inconclusive since only a single dose was applied. There was not enough evidence to show that pretreatment with COX-2 inhibitor suppressed the activity of COX-2 in brain tissues efficiently as a result of rapid clearance/degraded activity. Considering different biological end points, radiation induced non-targeted response *in vivo* appears to be a tissue specific observation. In the present study, a consecutive five day treatment regimen reduced the COX-2 as well as 8-OHdG levels in non-targeted bronchial epithelial cells by 30% (*P*\<0.05).

A better understanding of the mechanisms of non-targeted effects will be invaluable to assess the clinical relevance of bystander effects and ways in which the bystander phenomenon can be manipulated to increase therapeutic gain in radiotherapy.
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![Pretreatment of COX-2 inhibitor suppresses induction of COX-2, PGE2 and 8-OHdG in non-targeted lung tissues after partial body irradiation. (**A**) Western blot data show pretreatment with Nimesulide did not affect COX-2 basal expression in lung tissues but reduced COX-2 expression levels in non-targeted lung tissues 24 h after lower abdominal irradiation. (**B**) COX-2 was significantly reduced in non-targeted bronchial epithelial cells at 24 h after partial body irradiation. A representative microscopic field from each group is shown under 10 × magnification. Bar represents 200 *μ*m. (**C**) Nimesulide reduced PGE2 production in non-targeted lung tissues. Pooled data from three animals and error bars: means±s.e.m. Quantification of COX-2 staining intensity in bronchial epithelial cells in Nimesulide-treated mice showed a significant reduction relative to controls with asterisks (**\*\****P*\<0.01, student\'s *t* test). (**D**) Pretreatment with Nimesulide suppressed the induction of 8-OHdG in non-targeted lung tissues. 8-OHdG was localised predominantly in bronchial epithelial cells at 24 h after partial body irradiation. A representative microscopic field from each group is shown under 40 × magnification. Bar represents 50 *μ*m. Statistical comparison between DMSO and Nimesulide groups with similar partial body irradiation is marked with asterisks (**\*\****P*\<0.01, Student\'s *t*-test). Error bars indicate standard errors of the means (s.e.m.) for 20 independent microscopic fields from three different mice.](bjc201353f1){#fig1}

![Changes of cytokines in plasma after partial body irradiation. Time course of the released forms of TGF-*β* (**A**) and TNF-*α* (**B**) in plasma after lower abdomen irradiation with 5 Gy of X-rays is shown. Three animals per dosage and time point were analysed.](bjc201353f2){#fig2}

![**TGF-*β* but not TNF-*α* is induced in bystander lung tissues after lower abdominal irradiation.** (**A**) Western blot data show expression of TGF-*β* and TNF-*α* in non-targeted lung tissues as a function of day postirradiation. Quantification of relative fold changes of TGF-*β* and TNF-*α* expression relative to *β*-actin of each group is shown. (**B**) Similar to A, but showing expression levels of TGFBR1 and TGFBR2 in non-targeted lung tissues at different time points postirradiation. (**C**) Western blot data showing expression levels of TNF-*α* and TNF-*α* receptor 1 in bystander lung tissue as a function of time post-irradiation. *β*-actin levels were used as a loading control. (**D**) Different expression level of TGFBR1 in lung and liver tissues. Lungs and livers are from three independent non-irradiated animals from control group.](bjc201353f3){#fig3}

![**Differential distribution of TGF-*β* and TGFBR1 in non-targeted lung tissues.** (**A**) Representative immunohistochemical staining of TGF-*β* in lung tissue section of animals irradiated with a whole-body dose of 6cGy (scattering dose) of X-rays (left) and those from partial body irradiated animals (right) under 40 × magnification. Bar represents 50 *μ*m. (**B**) Quantification of TGF-*β* staining in bronchial epithelial cells of each group. The whole-body irradiated group receiving a 6cGy scattering dose of X-rays, which gave similar expression levels as non-irradiated animals, was used as controls. (**C**) and (**D**) Similar to descriptions for **A** and **B** but for TGFBR1 expression, under 40 × magnification. Bar represents 20 *μ*m. Statistical comparison between control and irradiation groups marked with asterisks (\**P*\<0·05, Student\'s *t*-test). Error bars indicate the s.e. of the mean (s.e.m.) for 20 independent microscopic fields from three different mice.](bjc201353f4){#fig4}

![**Activation of multiple TGF-*β* related signalling pathways in non-targeted lung tissues.** (**A**) Western blot data show expression of phosphorylated-Smad-2 but not phosphorylated-Rac1 in non-targeted lung tissues. (**B**--**E**) Activation of Smad-independent pathways in non-targeted lung. The kinetics of activation of ERK, JNK, NF*κ*B and AKT in non-targeted lung tissues is shown. A total of three animals were used per time point and representative expression level from a single animal is shown. The rest of the animals of each group demonstrated similar trends. Beta-actin levels were used as loading controls in all samples.](bjc201353f5){#fig5}

![A signalling model for the induction of non-targeted responses in the out of field lung tissues after lower abdomen irradiation. Lower abdomen irradiation induces TGF-*β* ligands and receptors in non-targeted lung tissues but not released forms in the blood. TGF-*β* in stromal regions binds to its corresponding receptors on bronchial epithelial cells and activates a range of signalling pathways involving ERK, JNK, AKT, NF*κ*B and Smad2, which lead to the upregulation of COX-2 in non-targeted lung tissues. COX-2 further induces prostaglandin production, oxidative DNA damage and mutagenesis in the non-targeted lung tissues.](bjc201353f6){#fig6}
